Authors

Matthew Royle, Ph.D.

Partner

Read More

Dr. Manja Epping

Partner

Read More

Evelyne Friedel

Partner

Read More

Judith Krens

Partner

Read More
Authors

Matthew Royle, Ph.D.

Partner

Read More

Dr. Manja Epping

Partner

Read More

Evelyne Friedel

Partner

Read More

Judith Krens

Partner

Read More

21 March 2019 |

Recent developments in biosimilars settlements, market landscape and antitrust scrutiny

Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets. Activity relating to biosimilars has intensified in the US since the introduction of the BPCIA in 2009 and in Europe since the first biosimilars were authorised in 2006. Successfully bringing a biosimilar to market raises distinct challenges as compared to small molecule generics, and there are significant differences to understand between the approaches to US and European laws, regulations, and markets.

Session 1 of this series focusses on key factors decision makers need to be aware of when considering settlement, including:

  • Recent biosimilars settlement agreements in the US and Europe
  • Legal requirements driving settlement in Europe
  • FTC scrutiny of biosimilars settlements in the US


Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Life sciences & healthcare

Supplementary protection certificates: where are we and where are we going? (an update)

15 February 2019

by multiple authors

Click here to find out more
Life sciences & healthcare

The what, why and how of the UK Supreme Court Warner-Lambert decision

29 November 2018

by multiple authors

Click here to find out more

Related events

There are no upcoming events